The Biotech Growth Trust PLC (BIOG) has disclosed a director shareholding notification confirming that Non-Executive Director Jennifer Harries acquired 750 ordinary 25p shares on 20 November 2026. The transaction was executed on the London Stock Exchange at a price of 1353.5989 pence per share. Such purchases by persons discharging managerial responsibilities (PDMRs) are required disclosures under market transparency rules and are often monitored by investors as a signal of insider sentiment towards the trust's prospects.

Key Points

  • The Biotech Growth Trust PLC (BIOG)
  • Non-Executive Director Jennifer Harries acquired 750 ordinary 25p shares on 20 November 2026
  • Transaction price: 1353.5989 pence per share; executed on the London Stock Exchange
  • Investors may watch for further PDMR activity or updates to the trust's portfolio positioning

Jennifer Harries Purchases BIOG Shares on London Stock Exchange at 1353.60p

The announcement, filed as an initial notification, confirms that Jennifer Harries, in her capacity as a Non-Executive Director of The Biotech Growth Trust PLC, acquired 750 ordinary shares with a nominal value of 25 pence each. The shares were purchased at 1353.5989 pence per share on the London Stock Exchange. The notification was made on behalf of the company by Katherine Manson, acting for and on behalf of Frostrow Capital LLP, which serves as Company Secretary to The Biotech Growth Trust PLC. The LEI for the trust is recorded as 549300Z41EP32MI2DN29.

About The Biotech Growth Trust and Its Role as a Specialist Investment Vehicle

The Biotech Growth Trust PLC is a closed-ended investment trust focused on providing shareholders with exposure to the global biotechnology sector. The trust's investment objective centres on achieving capital growth through a portfolio of biotechnology and related life sciences equities. As a listed investment trust trading on the London Stock Exchange, its performance is closely tied to developments across global biotech markets, including clinical trial outcomes, regulatory decisions, and broader sector sentiment. Frostrow Capital LLP provides company secretarial services, as evidenced by its role in submitting this regulatory notification.

PDMR Disclosure Requirements and What This Transaction Signals

Under UK market transparency regulations, directors and other persons discharging managerial responsibilities are required to publicly disclose transactions in the securities of their company. This filing represents an initial notification, meaning it has not been amended or restated. The acquisition of shares by a Non-Executive Director, while modest in volume, is a matter of public record that investors may choose to factor into their own assessments of board conviction. The company did not disclose any further commentary on the rationale behind the purchase in the announcement.

Frostrow Capital LLP Files Notification on Behalf of The Biotech Growth Trust

The notification was authorised by Katherine Manson, acting for and on behalf of Frostrow Capital LLP in its role as Company Secretary to The Biotech Growth Trust PLC. The filing identifies the financial instrument as ordinary 25p shares carrying the identification code GB0000385517. The aggregated volume and price data confirm a single transaction of 750 shares at 1353.5989 pence per share, with no additional tranches or separate transaction dates referenced within this disclosure.